Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Interleukin-16 as a marker of Sézary syndrome onset and stage. J Clin Immunol 2011 Feb;31(1):39-50

Date

09/30/2010

Pubmed ID

20878214

Pubmed Central ID

PMC4863446

DOI

10.1007/s10875-010-9464-8

Scopus ID

2-s2.0-79953906721 (requires institutional sign-in at Scopus site)   25 Citations

Abstract

INTRODUCTION: Sézary syndrome is one of the most common forms of cutaneous T cell lymphoma (CTCL). It is characterized by skin infiltration of malignant T cells. We examined interleukin-16, a potent T cell chemoattractant and cell-cycle regulator, as a prospective marker of disease onset and stage.

METHODS: The correlation of total intracellular interleukin-16 and surface CD26 was studied by flow cytometry. Confocal microscopy was performed to determine localization of interleukin-16 at different stages of the disease. The levels of interleukin-16 in plasma and culture supernatants were examined by enzyme-linked immunoassay. Additionally, lymphocytes from stage IB patients were cultured in the presence of interleukin-16 alone and in combination with interleukin-15, and their ability to survive and proliferate was determined by cell counts and [3H]TdR incorporation.

RESULTS: The data indicate that loss of both nuclear and intracellular pro-interleukin-16 highly correspond to disease stage, with a concomitant increase in secreted mature interleukin-16 in both culture supernatants and patients' plasma that peaks at stage IB. Loss of intracellular interleukin-16 strongly corresponded to loss of surface CD26, which has been shown to occur with more advanced stage of CTCL. Nuclear translocation of pro-interleukin-16 was not observed in late stages of Sézary syndrome, indicating this loss is not reversible.

CONCLUSIONS: We propose that it is feasible to use plasma levels of IL-16 as a potential diagnostic marker of Sézary syndrome and to use loss of intracellular IL-16 as a prognostic indicator of disease severity and stage.

Author List

Richmond J, Tuzova M, Parks A, Adams N, Martin E, Tawa M, Morrison L, Chaney K, Kupper TS, Curiel-Lewandrowski C, Cruikshank W

Author

Keri S. Chaney MD Assistant Professor in the Dermatology department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Aged
Dipeptidyl Peptidase 4
Enzyme-Linked Immunosorbent Assay
Female
Flow Cytometry
Humans
Interleukin-16
Male
Middle Aged
Neoplasm Staging
Prognosis
Severity of Illness Index
Sezary Syndrome
Skin Neoplasms